DOCSLIB.ORG

Associations Between Genetically Predicted Blood Protein Biomarkers and Pancreatic 2 Cancer Risk 3

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Associations Between Genetically Predicted Blood Protein Biomarkers and Pancreatic 2 Cancer Risk 3 Author Manuscript Published OnlineFirst on May 21, 2020; DOI: 10.1158/1055-9965.EPI-20-0091 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Zhu et al. – Page 1 1 Associations between genetically predicted blood protein biomarkers and pancreatic 2 cancer risk 3 4 Jingjing Zhu 1, Xiang Shu 2, Xingyi Guo 2, Duo Liu 1,3, Jiandong Bao 2, Roger L Milne 4, 5, 6, 5 Graham G Giles 4, 5, 6, Chong Wu 7, Mengmeng Du 8, Emily White 9,10, Harvey A Risch11, Nuria 6 Malats 12, Eric J. Duell 13, Phyllis J. Goodman 14, Donghui Li 15, Paige Bracci 16, Verena Katzke 7 17, Rachel E Neale 18, Steven Gallinger 19, Stephen K Van Den Eeden 20, Alan A Arslan 21, 8 Federico Canzian 22, Charles Kooperberg 9, Laura E Beane-Freeman 23, Ghislaine Scelo 24, Kala 9 Visvanathan25, Christopher A. Haiman 26, Loïc Le Marchand 1, Herbert Yu 1, Gloria M Petersen 10 27, Rachael Stolzenberg-Solomon 23, Alison P Klein 25,28, Qiuyin Cai 2, Jirong Long 2, Xiao-Ou 11 Shu 2, Wei Zheng 2, Lang Wu 1 12 13 1. Cancer Epidemiology Division, Population Sciences in the Pacific Program, University of 14 Hawaii Cancer Center, University of Hawaii at Manoa, Honolulu, HI, USA 15 2. Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, 16 Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA 17 3. Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, China 18 4. Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia 19 5. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global 20 Health, the University of Melbourne, VIC, Australia 21 6. Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, 22 Clayton, VIC, Australia 23 7. Department of Statistics, Florida State University, Tallahassee, FL, USA 24 8. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New 25 York, NY, USA 26 9. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, 27 USA 28 10. Department of Epidemiology, University of Washington, Seattle, WA, USA 29 11. Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, 30 CT, USA 31 12. Spanish National Cancer Research Centre (CNIO) and CIBERONC, Madrid, Spain 32 13. Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of 33 Oncology (ICO-IDIBELL), L'Hospitalet de Llobregat, Spain 34 14. SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA 35 15. Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson 36 Cancer Center, Houston, TX, USA 37 16. Department of Epidemiology and Biostatistics, University of California San Francisco, San 38 Francisco, CA, USA 39 17. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, 40 Germany 41 18. Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD, 42 Australia 43 19. Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada 44 20. Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA 45 21. Department of Obstetrics and Gynecology, New York University School of Medicine, USA Downloaded from cebp.aacrjournals.org on October 1, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 21, 2020; DOI: 10.1158/1055-9965.EPI-20-0091 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Zhu et al. – Page 2 46 22. Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, 47 Germany 48 23. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes 49 of Health, Rockville, MD, USA 50 24. Genetic Epidemiology Group, Section of Genetics, International Agency for Research on 51 Cancer, World Health Organization, Lyon, France 52 25. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, 53 MD, USA 54 26. Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of 55 Medicine, University of Southern California, Los Angeles, CA, 90033, USA 56 27. Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, 57 USA 58 28. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins 59 School of Medicine, Baltimore, MD, USA 60 61 Running title: Genetically predicted protein biomarkers for pancreatic cancer 62 63 Abbreviations list: 64 Pancreatic ductal adenocarcinoma (PDAC) 65 protein quantitative trait loci (pQTL) 66 Mendelian randomization (MR) 67 Genome-wide association studies (GWAS) 68 the Pancreatic Cancer Cohort Consortium (PanScan) 69 the Pancreatic Cancer Case-Control Consortium (PanC4) 70 quality control (QC) 71 Hardy-Weinberg equilibrium (HWE) 72 inverse variance weights (IVW) 73 odds ratios (ORs) 74 confidence intervals (CIs) 75 false discovery rate (FDR) 76 Ingenuity Pathway Analysis (IPA) 77 78 Corresponding to: Lang Wu, Cancer Epidemiology Division, Population Sciences in the Pacific 79 Program, University of Hawaii Cancer Center, University of Hawaii at Manoa, Honolulu, HI, 80 96813, USA. Email: [email protected]. Phone: (808)564-5965. 81 82 Competing financial interests 83 The authors declare no competing financial interests. 84 85 86 87 88 89 Downloaded from cebp.aacrjournals.org on October 1, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 21, 2020; DOI: 10.1158/1055-9965.EPI-20-0091 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Zhu et al. – Page 3 90 Abstract 91 Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies 92 with few known risk factors and biomarkers. Several blood protein biomarkers have been linked 93 to PDAC in previous studies, but these studies have assessed only a limited number of 94 biomarkers usually in small samples. In this study, we evaluated associations of circulating 95 protein levels and PDAC risk using genetic instruments. 96 Methods: To identify novel circulating protein biomarkers of PDAC, we studied 8,280 cases and 97 6,728 controls of European descent from the Pancreatic Cancer Cohort Consortium and the 98 Pancreatic Cancer Case-Control Consortium, using genetic instruments of protein quantitative 99 trait loci (pQTL). 100 Results: We observed associations between predicted concentrations of 38 proteins and PDAC 101 risk at a false discovery rate of < 0.05, including 23 of those proteins that showed an association 102 even after Bonferroni correction. These include the protein encoded by ABO, which has been 103 implicated as a potential target gene of PDAC risk variant. Eight of the identified proteins 104 (LMA2L, TM11D, IP-10, ADH1B, STOM, TENC1, DOCK9, and CRBB2) were associated with 105 PDAC risk after adjusting for previously reported PDAC risk variants (odds ratio ranged from 106 0.79 to 1.52). Pathway enrichment analysis showed that the encoding genes for implicated 107 proteins were significantly enriched in cancer-related pathways, such as STAT3 and IL-15 108 production. 109 Conclusions: We identified 38 candidates of protein biomarkers for PDAC risk. 110 Impact: This study identifies novel protein biomarker candidates for PDAC, which if validated 111 by additional studies, may contribute to the etiological understanding of PDAC development. 112 Key words: Biomarkers, epidemiology, genetics, pancreatic cancer, risk 113 Downloaded from cebp.aacrjournals.org on October 1, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 21, 2020; DOI: 10.1158/1055-9965.EPI-20-0091 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Zhu et al. – Page 4 114 Introduction 115 Pancreatic cancer, 95% of which is pancreatic ductal adenocarcinoma (PDAC), is the 116 second most commonly diagnosed gastrointestinal malignancy and the third leading cause of 117 cancer-related death in the United States (US) (1). With a five-year survival of 8%, the 118 incidence of pancreatic cancer keeps increasing in the US (2). Because pancreatic cancer is 119 typically asymptomatic in early stages, most patients are diagnosed at an advanced stage, which 120 precludes the possible application of curative surgery. Therefore, identifying biomarkers that 121 would contribute to screening or early diagnosis in high-risk populations may improve pancreatic 122 cancer outcomes. Serum CA 19-9 is currently the only biomarker for pancreatic cancer used in 123 clinical settings. However, it is mainly used for diagnosing symptomatic patients, and monitoring 124 disease prognosis and response to treatment (3). Besides CA 19-9, several other blood circulating 125 proteins have been reported to be potentially associated with pancreatic cancer risk, such as 126 CA242, PIVKA-II, PAM4, S100A6, OPN, RBM6, EphA2 and OPG (4–7), but the results in 127 those studies are inconsistent. For example, those studies often only involved a small sample size 128 and evaluated a few candidate proteins, and were often limited by a lack of external validation. 129 Additionally, due to the observational study design, they were potentially subject to selection 130 bias and residual and unmeasured confounding. 131 Mendelian randomization (MR) analysis is a widely applied
Load more

Recommended publications
  • Differential Expression of the CCN Family Members Cyr61, CTGF and Nov in Human Breast Cancer
    Endocrine-Related Cancer (2004) 11 781–791 Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer Wen G Jiang, Gareth Watkins, Oystein Fodstad 1, Anthony Douglas-Jones 2, Kefah Mokbel 3 and Robert E Mansel Metastasis & Angiogenesis Research Group, University of Wales College of Medicine, Cardiff University, Cardiff, UK 1Cancer Research Institute, University of South Alabama, Mobile, AL, USA 2Pathology, University of Wales College of Medicine, Cardiff University, Cardiff, UK 3Department of Surgery, St George Hospital, London, UK (Requests for offprints should be addressed to W G Jiang; Email: [email protected]) Abstract The CCN family members cysteine-rich 61 (Cyr61/CCN1), connective tissue growth factor (CTGF/ CCN2) and nephroblastoma over-expressed (Nov/CCN3) play diverse roles in cells, are known to regulate cell growth, adhesion, matrix production and migration and are involved in endocrine- regulated pathways in various cell types. The role of these molecules in cancer remains controversial. In a cohort of 122 human breast tumours (together with 32 normal breast tissues) we have analysed the expression of all three CCN members at the mRNA and protein levels. Significantly higher levels of Cyr61 ðP ¼ 0:02Þ, but low levels of CTGF and Nov, were seen in tumour tissues compared with normal tissues. Significantly raised levels of Cyr61 were associated with poor prognosis ðP ¼ 0:02Þ, nodal involvement ðP ¼ 0:03Þ and metastatic disease ðP ¼ 0:016Þ. Patients who died of breast cancer also had high levels of Cyr61. In contrast, CTGF in patients with poor prognosis ðP ¼ 0:021Þ, metastasis ðP ¼ 0:012Þ, local recurrence ðP ¼ 0:0024Þ and mortality ðP ¼ 0:0072Þ had markedly reduced levels.
    [Show full text]
  • Genetic Analysis of the Roles of Hh, FGF8, and Nodal Signaling During Catecholaminergic System Development in the Zebrafish Brain
    The Journal of Neuroscience, July 2, 2003 • 23(13):5507–5519 • 5507 Development/Plasticity/Repair Genetic Analysis of the Roles of Hh, FGF8, and Nodal Signaling during Catecholaminergic System Development in the Zebrafish Brain Jochen Holzschuh, Giselbert Hauptmann, and Wolfgang Driever Developmental Biology, Institute Biology 1, University of Freiburg, D-79104 Freiburg, Germany CNS catecholaminergic neurons can be distinguished by their neurotransmitters as dopaminergic or noradrenergic and form in distinct regions at characteristic embryonic stages. This raises the question of whether all catecholaminergic neurons of one transmitter type are specified by the same set of factors. Therefore, we performed genetic analyses to define signaling requirements for the specification of distinct clusters of catecholaminergic neurons in zebrafish. In mutants affecting midbrain–hindbrain boundary (MHB) organizer for- mation, the earliest ventral diencephalic dopaminergic neurons appear normal. However, after2dofdevelopment, we observed fewer cells than in wild types, which suggests that the MHB provides proliferation or survival factors rather than specifying ventral diencephalic dopaminergic clusters. In hedgehog (Hh) pathway mutants, the formation of catecholaminergic neurons is affected only in the pretectal cluster. Surprisingly, neither fibroblast growth factor 8 (FGF8) alone nor in combination with Hh signaling is required for specification of early developing dopaminergic neurons. We analyzed the formation of prosomeric territories in the forebrain of Hh and Nodal pathway mutants to determine whether the absence of specific dopaminergic clusters may be caused by early patterning defects ablating corre- sponding parts of the CNS. In Nodal pathway mutants, ventral diencephalic and pretectal catecholaminergic neurons fail to develop, whereas both anatomical structures form at least in part.
    [Show full text]
  • Supplemental Figure 1. Vimentin
    Double mutant specific genes Transcript gene_assignment Gene Symbol RefSeq FDR Fold- FDR Fold- FDR Fold- ID (single vs. Change (double Change (double Change wt) (single vs. wt) (double vs. single) (double vs. wt) vs. wt) vs. single) 10485013 BC085239 // 1110051M20Rik // RIKEN cDNA 1110051M20 gene // 2 E1 // 228356 /// NM 1110051M20Ri BC085239 0.164013 -1.38517 0.0345128 -2.24228 0.154535 -1.61877 k 10358717 NM_197990 // 1700025G04Rik // RIKEN cDNA 1700025G04 gene // 1 G2 // 69399 /// BC 1700025G04Rik NM_197990 0.142593 -1.37878 0.0212926 -3.13385 0.093068 -2.27291 10358713 NM_197990 // 1700025G04Rik // RIKEN cDNA 1700025G04 gene // 1 G2 // 69399 1700025G04Rik NM_197990 0.0655213 -1.71563 0.0222468 -2.32498 0.166843 -1.35517 10481312 NM_027283 // 1700026L06Rik // RIKEN cDNA 1700026L06 gene // 2 A3 // 69987 /// EN 1700026L06Rik NM_027283 0.0503754 -1.46385 0.0140999 -2.19537 0.0825609 -1.49972 10351465 BC150846 // 1700084C01Rik // RIKEN cDNA 1700084C01 gene // 1 H3 // 78465 /// NM_ 1700084C01Rik BC150846 0.107391 -1.5916 0.0385418 -2.05801 0.295457 -1.29305 10569654 AK007416 // 1810010D01Rik // RIKEN cDNA 1810010D01 gene // 7 F5 // 381935 /// XR 1810010D01Rik AK007416 0.145576 1.69432 0.0476957 2.51662 0.288571 1.48533 10508883 NM_001083916 // 1810019J16Rik // RIKEN cDNA 1810019J16 gene // 4 D2.3 // 69073 / 1810019J16Rik NM_001083916 0.0533206 1.57139 0.0145433 2.56417 0.0836674 1.63179 10585282 ENSMUST00000050829 // 2010007H06Rik // RIKEN cDNA 2010007H06 gene // --- // 6984 2010007H06Rik ENSMUST00000050829 0.129914 -1.71998 0.0434862 -2.51672
    [Show full text]
  • Epha Receptors and Ephrin-A Ligands Are Upregulated by Monocytic
    Mukai et al. BMC Cell Biology (2017) 18:28 DOI 10.1186/s12860-017-0144-x RESEARCHARTICLE Open Access EphA receptors and ephrin-A ligands are upregulated by monocytic differentiation/ maturation and promote cell adhesion and protrusion formation in HL60 monocytes Midori Mukai, Norihiko Suruga, Noritaka Saeki and Kazushige Ogawa* Abstract Background: Eph signaling is known to induce contrasting cell behaviors such as promoting and inhibiting cell adhesion/ spreading by altering F-actin organization and influencing integrin activities. We have previously demonstrated that EphA2 stimulation by ephrin-A1 promotes cell adhesion through interaction with integrins and integrin ligands in two monocyte/ macrophage cell lines. Although mature mononuclear leukocytes express several members of the EphA/ephrin-A subclass, their expression has not been examined in monocytes undergoing during differentiation and maturation. Results: Using RT-PCR, we have shown that EphA2, ephrin-A1, and ephrin-A2 expression was upregulated in murine bone marrow mononuclear cells during monocyte maturation. Moreover, EphA2 and EphA4 expression was induced, and ephrin-A4 expression was upregulated, in a human promyelocytic leukemia cell line, HL60, along with monocyte differentiation toward the classical CD14++CD16− monocyte subset. Using RT-PCR and flow cytometry, we have also shown that expression levels of αL, αM, αX, and β2 integrin subunits were upregulated in HL60 cells along with monocyte differentiation while those of α4, α5, α6, and β1 subunits were unchanged. Using a cell attachment stripe assay, we have shown that stimulation by EphA as well as ephrin-A, likely promoted adhesion to an integrin ligand- coated surface in HL60 monocytes. Moreover, EphA and ephrin-A stimulation likely promoted the formation of protrusions in HL60 monocytes.
    [Show full text]
  • Supplemental Table S1
    Entrez Gene Symbol Gene Name Affymetrix EST Glomchip SAGE Stanford Literature HPA confirmed Gene ID Profiling profiling Profiling Profiling array profiling confirmed 1 2 A2M alpha-2-macroglobulin 0 0 0 1 0 2 10347 ABCA7 ATP-binding cassette, sub-family A (ABC1), member 7 1 0 0 0 0 3 10350 ABCA9 ATP-binding cassette, sub-family A (ABC1), member 9 1 0 0 0 0 4 10057 ABCC5 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 1 0 0 0 0 5 10060 ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 1 0 0 0 0 6 79575 ABHD8 abhydrolase domain containing 8 1 0 0 0 0 7 51225 ABI3 ABI gene family, member 3 1 0 1 0 0 8 29 ABR active BCR-related gene 1 0 0 0 0 9 25841 ABTB2 ankyrin repeat and BTB (POZ) domain containing 2 1 0 1 0 0 10 30 ACAA1 acetyl-Coenzyme A acyltransferase 1 (peroxisomal 3-oxoacyl-Coenzyme A thiol 0 1 0 0 0 11 43 ACHE acetylcholinesterase (Yt blood group) 1 0 0 0 0 12 58 ACTA1 actin, alpha 1, skeletal muscle 0 1 0 0 0 13 60 ACTB actin, beta 01000 1 14 71 ACTG1 actin, gamma 1 0 1 0 0 0 15 81 ACTN4 actinin, alpha 4 0 0 1 1 1 10700177 16 10096 ACTR3 ARP3 actin-related protein 3 homolog (yeast) 0 1 0 0 0 17 94 ACVRL1 activin A receptor type II-like 1 1 0 1 0 0 18 8038 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 1 0 0 0 0 19 8751 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 1 0 0 0 0 20 8728 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 1 0 0 0 0 21 81792 ADAMTS12 ADAM metallopeptidase with thrombospondin type 1 motif, 12 1 0 0 0 0 22 9507 ADAMTS4 ADAM metallopeptidase with thrombospondin type 1
    [Show full text]
  • The Extracellular Matrix Phenome Across Species
    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.06.980169; this version posted March 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. The extracellular matrix phenome across species Cyril Statzer1 and Collin Y. Ewald1* 1 Eidgenössische Technische Hochschule Zürich, Department of Health Sciences and Technology, Institute of Translational Medicine, Schwerzenbach-Zürich CH-8603, Switzerland *Corresponding authors: [email protected] (CYE) Keywords: Phenome, genotype-to-phenotype, matrisome, extracellular matrix, collagen, data mining. Highlights • 7.6% of the human phenome originates from variations in matrisome genes • 11’671 phenotypes are linked to matrisome genes of humans, mice, zebrafish, Drosophila, and C. elegans • Expected top ECM phenotypes are developmental, morphological and structural phenotypes • Nonobvious top ECM phenotypes include immune system, stress resilience, and age-related phenotypes 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.03.06.980169; this version posted March 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. 1 Abstract 2 Extracellular matrices are essential for cellular and organismal function. Recent 3 genome-wide and phenome-wide association studies started to reveal a broad 4 spectrum of phenotypes associated with genetic variants. However, the phenome or 5 spectrum of all phenotypes associated with genetic variants in extracellular matrix 6 genes is unknown.
    [Show full text]
  • Table S1 the Four Gene Sets Derived from Gene Expression Profiles of Escs and Differentiated Cells
    Table S1 The four gene sets derived from gene expression profiles of ESCs and differentiated cells Uniform High Uniform Low ES Up ES Down EntrezID GeneSymbol EntrezID GeneSymbol EntrezID GeneSymbol EntrezID GeneSymbol 269261 Rpl12 11354 Abpa 68239 Krt42 15132 Hbb-bh1 67891 Rpl4 11537 Cfd 26380 Esrrb 15126 Hba-x 55949 Eef1b2 11698 Ambn 73703 Dppa2 15111 Hand2 18148 Npm1 11730 Ang3 67374 Jam2 65255 Asb4 67427 Rps20 11731 Ang2 22702 Zfp42 17292 Mesp1 15481 Hspa8 11807 Apoa2 58865 Tdh 19737 Rgs5 100041686 LOC100041686 11814 Apoc3 26388 Ifi202b 225518 Prdm6 11983 Atpif1 11945 Atp4b 11614 Nr0b1 20378 Frzb 19241 Tmsb4x 12007 Azgp1 76815 Calcoco2 12767 Cxcr4 20116 Rps8 12044 Bcl2a1a 219132 D14Ertd668e 103889 Hoxb2 20103 Rps5 12047 Bcl2a1d 381411 Gm1967 17701 Msx1 14694 Gnb2l1 12049 Bcl2l10 20899 Stra8 23796 Aplnr 19941 Rpl26 12096 Bglap1 78625 1700061G19Rik 12627 Cfc1 12070 Ngfrap1 12097 Bglap2 21816 Tgm1 12622 Cer1 19989 Rpl7 12267 C3ar1 67405 Nts 21385 Tbx2 19896 Rpl10a 12279 C9 435337 EG435337 56720 Tdo2 20044 Rps14 12391 Cav3 545913 Zscan4d 16869 Lhx1 19175 Psmb6 12409 Cbr2 244448 Triml1 22253 Unc5c 22627 Ywhae 12477 Ctla4 69134 2200001I15Rik 14174 Fgf3 19951 Rpl32 12523 Cd84 66065 Hsd17b14 16542 Kdr 66152 1110020P15Rik 12524 Cd86 81879 Tcfcp2l1 15122 Hba-a1 66489 Rpl35 12640 Cga 17907 Mylpf 15414 Hoxb6 15519 Hsp90aa1 12642 Ch25h 26424 Nr5a2 210530 Leprel1 66483 Rpl36al 12655 Chi3l3 83560 Tex14 12338 Capn6 27370 Rps26 12796 Camp 17450 Morc1 20671 Sox17 66576 Uqcrh 12869 Cox8b 79455 Pdcl2 20613 Snai1 22154 Tubb5 12959 Cryba4 231821 Centa1 17897
    [Show full text]
  • Ephb3 Suppresses Non-Small-Cell Lung Cancer Metastasis Via a PP2A/RACK1/Akt Signalling Complex
    ARTICLE Received 7 Nov 2011 | Accepted 11 Jan 2012 | Published 7 Feb 2012 DOI: 10.1038/ncomms1675 EphB3 suppresses non-small-cell lung cancer metastasis via a PP2A/RACK1/Akt signalling complex Guo Li1, Xiao-Dan Ji1, Hong Gao1, Jiang-Sha Zhao1, Jun-Feng Xu1, Zhi-Jian Sun1, Yue-Zhen Deng1, Shuo Shi1, Yu-Xiong Feng1, Yin-Qiu Zhu1, Tao Wang2, Jing-Jing Li1 & Dong Xie1 Eph receptors are implicated in regulating the malignant progression of cancer. Here we find that despite overexpression of EphB3 in human non-small-cell lung cancer, as reported previously, the expression of its cognate ligands, either ephrin-B1 or ephrin-B2, is significantly downregulated, leading to reduced tyrosine phosphorylation of EphB3. Forced activation of EphB3 kinase in EphB3-overexpressing non-small-cell lung cancer cells inhibits cell migratory capability in vitro as well as metastatic seeding in vivo. Furthermore, we identify a novel EphB3-binding protein, the receptor for activated C-kinase 1, which mediates the assembly of a ternary signal complex comprising protein phosphatase 2A, Akt and itself in response to EphB3 activation, leading to reduced Akt phosphorylation and subsequent inhibition of cell migration. Our study reveals a novel tumour-suppressive signalling pathway associated with kinase-activated EphB3 in non-small-cell lung cancer, and provides a potential therapeutic strategy by activating EphB3 signalling, thus inhibiting tumour metastasis. 1 Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Graduate School of Chinese Academy of Sciences, Shanghai 200031, China. 2 The Eastern Hepatobiliary Surgery Hospital, the Second Military Medical University, Shanghai 200433, China.
    [Show full text]
  • Mutations in Mammalian Tolloid-Like 1 Gene Detected in Adult Patients with ASD
    European Journal of Human Genetics (2009) 17, 344 – 351 & 2009 Macmillan Publishers Limited All rights reserved 1018-4813/09 $32.00 www.nature.com/ejhg ARTICLE Mutations in mammalian tolloid-like 1 gene detected in adult patients with ASD Paweł Stan´ czak1, Joanna Witecka2, Anna Szydło2, Ewa Gutmajster2, Małgorzata Lisik2, Aleksandra Augus´ciak-Duma2, Maciej Tarnowski2, Tomasz Czekaj2, Hanna Czekaj2 and Aleksander L Sieron´ *,2 1Swietokrzyskie Center for Cardiology, Regional Hospital, Kielce, Poland; 2Department of General and Molecular Biology and Genetics, CoE for Research and Teaching of Molecular Biology of Matrix and Nanotechnology, CoE Network, BioMedTech ‘Silesia’, Medical University of Silesia, Katowice, Poland Atrial septal defect (ASD) is an incomplete septation of atria in human heart causing circulatory problems. Its frequency is estimated at one per 10 000. Actions of numerous genes have been linked to heart development. However, no single gene defect causing ASD has yet been identified. Incomplete heart septation similar to ASD was reported in transgenic mice with both inactive alleles of gene encoding mammalian zinc metalloprotease a mammalian tolloid-like 1 (tll1). Here, we have screened 19 ASD patients and 15 healthy age-matched individuals for mutations in TLL1 gene. All 22 exons were analyzed exon by exon for heteroduplex formation. Subsequently, DNA fragments forming heteroduplexes were sequenced. In four nonrelated patients, three missense mutations in coding sequence, and one single base change in the 50UTR have been detected. Two mutations (Met182Leu, and Ala238Val) were detected in ASD patients with the same clinical phenotype. As the second mutation locates immediately upstream of the catalytic zinc-binding signature, it might change the enzyme substrate specificity.
    [Show full text]
  • Noninvasive Sleep Monitoring in Large-Scale Screening of Knock-Out Mice
    bioRxiv preprint doi: https://doi.org/10.1101/517680; this version posted January 11, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Noninvasive sleep monitoring in large-scale screening of knock-out mice reveals novel sleep-related genes Shreyas S. Joshi1*, Mansi Sethi1*, Martin Striz1, Neil Cole2, James M. Denegre2, Jennifer Ryan2, Michael E. Lhamon3, Anuj Agarwal3, Steve Murray2, Robert E. Braun2, David W. Fardo4, Vivek Kumar2, Kevin D. Donohue3,5, Sridhar Sunderam6, Elissa J. Chesler2, Karen L. Svenson2, Bruce F. O'Hara1,3 1Dept. of Biology, University of Kentucky, Lexington, KY 40506, USA, 2The Jackson Laboratory, Bar Harbor, ME 04609, USA, 3Signal solutions, LLC, Lexington, KY 40503, USA, 4Dept. of Biostatistics, University of Kentucky, Lexington, KY 40536, USA, 5Dept. of Electrical and Computer Engineering, University of Kentucky, Lexington, KY 40506, USA. 6Dept. of Biomedical Engineering, University of Kentucky, Lexington, KY 40506, USA. *These authors contributed equally Address for correspondence and proofs: Shreyas S. Joshi, Ph.D. Dept. of Biology University of Kentucky 675 Rose Street 101 Morgan Building Lexington, KY 40506 U.S.A. Phone: (859) 257-2805 FAX: (859) 257-1717 Email: [email protected] Running title: Sleep changes in knockout mice bioRxiv preprint doi: https://doi.org/10.1101/517680; this version posted January 11, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Supplemental Table 1. Complete Gene Lists and GO Terms from Figure 3C
    Supplemental Table 1. Complete gene lists and GO terms from Figure 3C. Path 1 Genes: RP11-34P13.15, RP4-758J18.10, VWA1, CHD5, AZIN2, FOXO6, RP11-403I13.8, ARHGAP30, RGS4, LRRN2, RASSF5, SERTAD4, GJC2, RHOU, REEP1, FOXI3, SH3RF3, COL4A4, ZDHHC23, FGFR3, PPP2R2C, CTD-2031P19.4, RNF182, GRM4, PRR15, DGKI, CHMP4C, CALB1, SPAG1, KLF4, ENG, RET, GDF10, ADAMTS14, SPOCK2, MBL1P, ADAM8, LRP4-AS1, CARNS1, DGAT2, CRYAB, AP000783.1, OPCML, PLEKHG6, GDF3, EMP1, RASSF9, FAM101A, STON2, GREM1, ACTC1, CORO2B, FURIN, WFIKKN1, BAIAP3, TMC5, HS3ST4, ZFHX3, NLRP1, RASD1, CACNG4, EMILIN2, L3MBTL4, KLHL14, HMSD, RP11-849I19.1, SALL3, GADD45B, KANK3, CTC- 526N19.1, ZNF888, MMP9, BMP7, PIK3IP1, MCHR1, SYTL5, CAMK2N1, PINK1, ID3, PTPRU, MANEAL, MCOLN3, LRRC8C, NTNG1, KCNC4, RP11, 430C7.5, C1orf95, ID2-AS1, ID2, GDF7, KCNG3, RGPD8, PSD4, CCDC74B, BMPR2, KAT2B, LINC00693, ZNF654, FILIP1L, SH3TC1, CPEB2, NPFFR2, TRPC3, RP11-752L20.3, FAM198B, TLL1, CDH9, PDZD2, CHSY3, GALNT10, FOXQ1, ATXN1, ID4, COL11A2, CNR1, GTF2IP4, FZD1, PAX5, RP11-35N6.1, UNC5B, NKX1-2, FAM196A, EBF3, PRRG4, LRP4, SYT7, PLBD1, GRASP, ALX1, HIP1R, LPAR6, SLITRK6, C16orf89, RP11-491F9.1, MMP2, B3GNT9, NXPH3, TNRC6C-AS1, LDLRAD4, NOL4, SMAD7, HCN2, PDE4A, KANK2, SAMD1, EXOC3L2, IL11, EMILIN3, KCNB1, DOK5, EEF1A2, A4GALT, ADGRG2, ELF4, ABCD1 Term Count % PValue Genes regulation of pathway-restricted GDF3, SMAD7, GDF7, BMPR2, GDF10, GREM1, BMP7, LDLRAD4, SMAD protein phosphorylation 9 6.34 1.31E-08 ENG pathway-restricted SMAD protein GDF3, SMAD7, GDF7, BMPR2, GDF10, GREM1, BMP7, LDLRAD4, phosphorylation
    [Show full text]
  • Fgf8b Oncogene Mediates Proliferation and Invasion of Epstein–Barr Virus-Associated Nasopharyngeal Carcinoma Cells: Implication for Viral-Mediated Fgf8b Upregulation
    Oncogene (2011) 30, 1518–1530 & 2011 Macmillan Publishers Limited All rights reserved 0950-9232/11 www.nature.com/onc ORIGINAL ARTICLE FGF8b oncogene mediates proliferation and invasion of Epstein–Barr virus-associated nasopharyngeal carcinoma cells: implication for viral-mediated FGF8b upregulation VWY Lui1,7, DM-S Yau1,7, CS-F Cheung1, SCC Wong1, AK-C Chan2, Q Zhou1, EY-L Wong1, CPY Lau1, EKY Lam1, EP Hui1, B Hong1, CWC Hui1, AS-K Chan1, PKS Ng3, Y-K Ng4, K-W Lo5, CM Tsang6, SKW Tsui3, S-W Tsao6 and ATC Chan1 1State Key Laboratory of Oncology in South China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong; 2Department of Pathology, Queen Elizabeth Hospital, Hong Kong; 3School of Biomedical Sciences, Chinese University of Hong Kong, Hong Kong; 4Department of Surgery, Chinese University of Hong Kong, Hong Kong; 5Department of Anatomical and Cellular Pathology, Chinese University of Hong Kong, Hong Kong and 6Department of Anatomy, University of Hong Kong, Hong Kong The fibroblast growth factor 8b (FGF8b) oncogene is identified LMP1 as the first viral oncogene capable of known to be primarily involved in the tumorigenesis and directly inducing FGF8b (an important cellular oncogene) progression of hormone-related cancers. Its role in other expression in human cancer cells. This novel mechanism of epithelial cancers has not been investigated, except for viral-mediated FGF8 upregulation may implicate a new esophageal cancer, in which FGF8b overexpression was role of oncoviruses in human carcinogenesis. mainly found in tumor biopsies of male patients. These Oncogene (2011) 30, 1518–1530; doi:10.1038/onc.2010.529; observations were consistent with previous findings in published online 29 November 2010 these cancer types that the male sex-hormone androgen is responsible for FGF8b expression.
    [Show full text]